SU
Supriya Lifescience Ltd (SUPRIYA)
₹840.50
Mkt cap
₹6,765 Cr
P/E ratio
32.30
P/B
5.64
Div yield
0.12%
ROE
19.10%
ROCE
25.10%
EPS (TTM)
₹26.02
Book value
₹149
52W range
553–1,053
Sector
Healthcare
Supriya Lifescience is engaged in the manufacturing of Active pharmaceutical ingredients (APIs). As of March 31, 2021, the company produces 38 APIs focused on diverse therapeutic segments such as antihistamine, analgesic, anaesthetic, vitamin, anti-asthmatic and anti-allergic. [1]
Health check
Constructive
ValuationFair
ProfitabilityStrong
GrowthHigh
TechnicalsNeutral
52-week range
−20.14% from high₹841
₹553+51.89% from low₹1,053
Current
₹840.50
Prev close
₹840.00
Day
+0.06%
Price performance
1D
+0.06%
1W
+0.38%
1M
−9.44%
3M
+30.75%
6M
+16.12%
1Y
+16.69%
YTD
+11.98%
Financials
FRevenue, profit & margin
P/E ratio
32.3×
SUPRIYA is 5% below the sector median of 34.0×
SUPRIYA32.3×
Sector median34.0×
| Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 142 | 132 | 140 | 140 | 158 | 161 | 166 | 186 | 184 | 145 | 200 | 206 | 277 | |
| Expenses | 87 | 88 | 108 | 99 | 103 | 98 | 101 | 120 | 117 | 93 | 127 | 134 | 179 | |
| Operating Profit | 55 | 44 | 32 | 41 | 56 | 63 | 65 | 66 | 68 | 52 | 73 | 72 | 98 | |
| OPM % | 39% | 34% | 23% | 30% | 35% | 39% | 39% | 36% | 37% | 36% | 36% | 35% | 35% | |
| Other Income | 2 | 3 | 2 | 3 | 2 | 2 | 3 | 2 | 3 | 3 | 3 | 2 | 3 | |
| Interest | 1 | 1 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | |
| Depreciation | 3 | 4 | 4 | 4 | 4 | 5 | 5 | 5 | 6 | 6 | 7 | 7 | 8 | |
| Profit before tax | 53 | 43 | 30 | 40 | 53 | 60 | 62 | 63 | 64 | 47 | 68 | 67 | 92 | |
| Tax % | 28% | 33% | 20% | 26% | 31% | 25% | 26% | 25% | 21% | 27% | 26% | 26% | 19% | |
| Net Profit | 38 | 29 | 24 | 30 | 37 | 45 | 46 | 47 | 50 | 35 | 50 | 50 | 74 | |
| EPS in Rs | 4.75 | 3.54 | 2.97 | 3.70 | 4.59 | 5.55 | 5.73 | 5.81 | 6.26 | 4.32 | 6.27 | 6.17 | 9.22 | |
| Raw PDF |
Earnings
EResults dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
No reaction history yet.
No quarterly filings ingested yet.
Corporate actions
CLast 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Shareholding
Sas of Jun 202668.30%Promoter
Promoters68.30%
FIIs6.18%1.02
DIIs5.30%0.40
Public20.21%0.62
Ownership trend
Peers
P8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Sun Pharma.Inds. | ₹1,941.10 | 37.48 | 4,65,735 | 0.82% | 2,710 | +13.58% | 14,612 | +12.76% | 20.53% |
| Divi's Lab. | ₹7,248.50 | 73.36 | 1,92,425 | 0.41% | 751 | +13.44% | 2,831 | +9.52% | 21.97% |
| Torrent Pharma. | ₹4,961.50 | 86.11 | 1,88,720 | 0.77% | 364 | −20.58% | 4,197 | +41.84% | 15.19% |
| Cipla | ₹1,410.60 | 31.84 | 1,13,955 | 0.92% | 786 | −39.19% | 7,119 | +2.33% | 15.49% |
| Zydus Lifesci. | ₹1,108.70 | 20.38 | 1,10,593 | 0.09% | 1,341 | +21.92% | 7,587 | +16.22% | 21.14% |
| Lupin | ₹2,370.50 | 19.06 | 1,08,387 | 0.76% | 1,469 | +101.49% | 7,475 | +31.89% | 29.93% |
| Mankind Pharma | ₹2,507.20 | 51.44 | 1,03,546 | 0.04% | 559 | +34.23% | 3,443 | +11.81% | 13.53% |
| Supriya Lifesci. | ₹840.50 | 32.29 | 6,765 | 0.12% | 74 | +47.34% | 277 | +50.20% | 25.13% |
| Median: 157 Co. | ₹432.05 | 34.03 | 1,978 | 0.10% | 15 | +28.10% | 176 | +17.66% | 15.10% |
Filings
DAnnual reports5
Concall transcripts48
TranscriptMay 2026PPTMay 2026RECMay 2026TranscriptFeb 2026PPTFeb 2026TranscriptNov 2025PPTNov 2025RECNov 2025TranscriptAug 2025PPTAug 2025RECAug 2025TranscriptMay 2025PPTMay 2025RECMay 2025TranscriptJan 2025PPTJan 2025RECJan 2025TranscriptNov 2024PPTNov 2024RECNov 2024TranscriptAug 2024PPTAug 2024RECAug 2024TranscriptJun 2024
Credit ratings6
Announcements5
Announcement under Regulation 30 (LODR)-Newspaper Publication 1d - Please find attached copy of Newspaper Publication of Postal Ballot Notice.Shareholder Meeting / Postal Ballot-Notice of Postal Ballot 21 Jul - Postal ballot notice for reappointment of Balasaheb Sawant as Whole Time Director from May 26, 2026 to May 25, 2029.Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 9 Jul - Enclosed herewith is the Certificate under Regulation 74 (5) of SEBI (DP) Regulations, 2018, receivedRTA.Announcement Under Regulation 30 Of SEBI (LODR) Regulations, 2015. 4 Jul - On July 3, 2026, Customs initiated NDPS proceedings against GM Sreekant Sreedharan; custody till July 17.Email Communication To Shareholders Regarding Dividend Taxation Provisions. 23 Jun - Sharesholder communication on dividend TDS; board recommended Re. 1 final dividend for FY26, subject to AGM approval.